C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 27 PLN -0.18%
Market Cap: 1.5B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celon Pharma SA
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Other Current Assets
zł3.7m
CAGR 3-Years
-21%
CAGR 5-Years
0%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Other Current Assets
zł869.5k
CAGR 3-Years
67%
CAGR 5-Years
56%
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.2 PLN
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Other Current Assets?
Other Current Assets
3.7m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Other Current Assets amounts to 3.7m PLN.

What is Celon Pharma SA's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
0%

Over the last year, the Other Current Assets growth was 26%. The average annual Other Current Assets growth rates for Celon Pharma SA have been -21% over the past three years .

Back to Top